These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 2682370)
21. [Critical study of current tumoral markers]. Touitou Y; Bogdan A Bull Cancer; 1988; 75(3):247-62. PubMed ID: 2453233 [TBL] [Abstract][Full Text] [Related]
22. Serum tumor markers in colorectal cancer staging, grading, and follow-up. Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835 [TBL] [Abstract][Full Text] [Related]
23. [The tumor markers CEA, TPA and CA 19-9 and ferritin and osteocalcin in follow-up studies in breast cancer]. Schatz C; von Lieven H; Mulders M; Rowold J; Stracke H; Müller H; Grebe SF; Schatz H Wien Klin Wochenschr; 1985 Dec; 97(23):873-9. PubMed ID: 3878042 [TBL] [Abstract][Full Text] [Related]
24. Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts. Yang JM; Southern JF; Warshaw AL; Lewandrowski KB Am J Surg; 1996 Jan; 171(1):126-9; discussion 129-30. PubMed ID: 8554126 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of micro-leukocyte adherence inhibition as an immunodiagnostic test for pancreatic cancer. Goldrosen MH; Russo AJ; Howell JH; Leveson SH; Moore MC; Holyoke ED; Douglass HO Cancer Res; 1979 Feb; 39(2 Pt 2):633-7. PubMed ID: 367589 [No Abstract] [Full Text] [Related]
26. [Importance of the tissue polypeptide antigen level in neoplastic patients. Its correlation with other tumor markers]. Ruibal A; Durán P; Lafuerza A; Bodi R; Solé LA; Rubio D; Ibarz L; De Torres JA; Domenech-Torné FM; Salvador L Rev Esp Oncol; 1984; 31(3):409-14. PubMed ID: 6546169 [TBL] [Abstract][Full Text] [Related]
27. [Study on the tumor immunity of renal cell carcinoma--with special reference to the significance of leukocyte adherence inhibition test]. Okada Y Hinyokika Kiyo; 1984 Oct; 30(10):1367-77. PubMed ID: 6395679 [TBL] [Abstract][Full Text] [Related]
28. CA 15-3, mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients. Cohen AD; Gopas J; Karplus G; Cohen Y Isr J Med Sci; 1995; 31(2-3):155-9. PubMed ID: 7744585 [TBL] [Abstract][Full Text] [Related]
29. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer]. Negishi Y; Furuno K; Sano Y; Hirata T; Utsunomiya A; Nakajima H; Okabe K; Shimizu K; Akiya K; Fujiwara Y Gan No Rinsho; 1985 May; 31(6 Suppl):655-63. PubMed ID: 2993692 [TBL] [Abstract][Full Text] [Related]
30. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer]. Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018 [TBL] [Abstract][Full Text] [Related]
31. [Clinical significance of the determination of serum carbohydrate antigen 19-9 in patients with carcinoma of the stomach and colorectum]. Hamazoe R; Yoshioka H; Furumoto T; Kanayama H; Shimizu N; Maeta M; Koga S Gan No Rinsho; 1985 Aug; 31(10):1287-92. PubMed ID: 3863968 [TBL] [Abstract][Full Text] [Related]
32. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. Takasaki H; Uchida E; Tempero MA; Burnett DA; Metzgar RS; Pour PM Cancer Res; 1988 Mar; 48(6):1435-8. PubMed ID: 3162196 [TBL] [Abstract][Full Text] [Related]
33. [Clinical evaluation of various tumor markers in pleural effusion and in the serum]. Jibiki K; Abe Y; Takeda M; Iwachika C; Odagiri E; Demura R; Demura H Gan No Rinsho; 1989 Aug; 35(9):991-8. PubMed ID: 2769951 [TBL] [Abstract][Full Text] [Related]
34. Preoperative serum markers in carcinoma of the rectum and rectosigmoid. II. Prediction of prognosis. Ståhle E; Glimelius B; Bergström R; Påhlman L Eur J Surg Oncol; 1988 Aug; 14(4):287-96. PubMed ID: 3165870 [TBL] [Abstract][Full Text] [Related]
35. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer]. Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515 [TBL] [Abstract][Full Text] [Related]
36. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer. Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536 [TBL] [Abstract][Full Text] [Related]
37. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease. Blind PJ; Dahlgren ST Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420 [TBL] [Abstract][Full Text] [Related]
38. [Serum tissue polypeptide antigen in the differential diagnosis of chronic pancreatitis and exocrine pancreatic tumors. Preliminary results]. Ruibal A; Encabo G Rev Esp Oncol; 1983; 30(3):313-6. PubMed ID: 6571374 [TBL] [Abstract][Full Text] [Related]
39. Expression of monoclonal antibody-defined tumor markers in four carcinomas. Wu JT Ann Clin Lab Sci; 1989; 19(1):17-26. PubMed ID: 2916833 [TBL] [Abstract][Full Text] [Related]
40. [Carbohydrate antigen CA 19-9: value in pancreatic pathology]. Venot J; Vincent D; Gainant A; Descottes B; Cessot F; Beck C Gastroenterol Clin Biol; 1986 Mar; 10(3):208-10. PubMed ID: 3460925 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]